Tokyo (July 25, 2002) Eisai Inc. (Headquarters: New Jersey, Chairman: Soichi Matsuno), a U.S. subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo, President: Haruo Naito) has recently entered into a collaborative agreement with Pfizer Inc. in which Eisai has exclusive U.S. rights to promote Pfizer's anti-seizure product, Cerebyx
(fosphenytoin sodium injection).
Under this agreement, Eisai will be responsible for sales and marketing, while Pfizer will be responsible for manufacturing and distribution in the U.S.
Cerebyx is a water-based injectable anticonvulsant used in the hospital setting to control generalized convulsive status epilepticus (SE), to prevent and treat seizures occurring during neurosurgery and as a short-term replacement for oral phenytoin when other means of phenytoin are unavailable, inappropriate or deemed less advantageous. Following intravenous or intramuscular administration of Cerebyx, fosphenytoin is converted to the anticonvulsant phenytoin.
This isthe second agreement between Eisai and Pfizer. Pfizer also copromotes Aricept (donepezil hydrochloride tablets), a product developed by Eisai for the treatment of mild to moderate Alzheimer's disease. With this agreement, we expect to make additional quality of life contributions to patients in the field of neurology.
